SummaryRMgm-4405
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 29253313 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii 17XNL |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Steel RWJ, Kappe SHI |
Name Group/Department | Center for Infectious Disease Research |
Name Institute | formerly Seattle Biomedical Research Institute |
City | Seattle |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4405 |
Principal name | Py s4/celtos(-) |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Normal gametocyte and ookinete production. Surprisingly PPy s4/celtos¯ parasites also established a low-level mosquito midgut infection. |
Oocyst | Normal gametocyte and ookinete production. Surprisingly Py s4/celtos¯ parasites also established a low-level mosquito midgut infection. Whereas the number of oocysts per midgut stayed stable between days 7 – 11 for Py WT, oocyst numbers for Py s4/celtos¯ parasites declined throughout this period. The fraction of midguts infected with Py s4/celtos¯ declined markedly from day 7 - 11, by which time oocysts were only occasionally observed and these exhibited defects in sporulation compared to Py WT oocysts. Combined, the data suggest that Py S4/CelTOS has an important role during oocyst survival and/or sporogenesis in addition to the previously reported role in ookinete traversal of the midgut epithelium. |
Sporozoite | No salivary gland sporozoites. |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PY17X_1434600 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1216600 | ||||||||||||||||||||||||
Gene product | cell traversal protein for ookinetes and sporozoites | ||||||||||||||||||||||||
Gene product: Alternative name | CelTOS, S4 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | To generate Py s4/celtos¯, two DNA fragments containing approximately 800 bp of the 5′ UTR and 3′ UTR of Py S4/CelTOS were amplified from WT Py 17XNL genomic DNA and cloned into the pDEF vector (BEI Resources). | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |